Vanda Salutari
A5040656664- Ovarian cancer diagnosis and treatment
- PARP inhibition in cancer therapy
- Endometrial and Cervical Cancer Treatments
- BRCA gene mutations in cancer
- Intraperitoneal and Appendiceal Malignancies
- Renal cell carcinoma treatment
- Estrogen and related hormone effects
- Cancer Immunotherapy and Biomarkers
- Inflammatory mediators and NSAID effects
- Colorectal and Anal Carcinomas
- Immunotherapy and Immune Responses
- Toxin Mechanisms and Immunotoxins
- Lung Cancer Research Studies
- Sarcoma Diagnosis and Treatment
- Reproductive Biology and Fertility
- Cervical Cancer and HPV Research
- Cancer Genomics and Diagnostics
- Cancer Mechanisms and Therapy
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Peptidase Inhibition and Analysis
- Endometriosis Research and Treatment
- Immune Cell Function and Interaction
- Colorectal Cancer Treatments and Studies
- Neuroendocrine Tumor Research Advances
Agostino Gemelli University Polyclinic
2015-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2020-2024
Università Cattolica del Sacro Cuore
2008-2021
Woman's Hospital
2021
University of Campania "Luigi Vanvitelli"
2017
Sapienza University of Rome
2007-2014
Catholic University of America
2004-2012
Gynecologic Oncology Group
2006
Carboplatin/paclitaxel is the standard first-line chemotherapy for patients with advanced ovarian cancer. Multicentre Italian Trials in Ovarian Cancer-2 (MITO-2), an academic multicenter phase III trial, tested whether carboplatin/pegylated liposomal doxorubicin (PLD) was more effective than chemotherapy.Chemotherapy-naive stage IC to IV cancer (age ≤ 75 years; Eastern Cooperative Oncology Group performance status 2) were randomly assigned carboplatin area under curve (AUC) 5 plus paclitaxel...
PURPOSE To investigate whether the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to secondary cytoreductive surgery (SCS) without neoadjuvant has a benefit on progression-free survival (PFS), as opposed SCS alone in patients with platinum-sensitive recurrent epithelial ovarian cancer (platinum-free interval, >6 months). METHODS This was multicenter randomized phase III study. Random assignment performed at time cases residual tumor ≤0.25 cm. HIPEC cisplatin (CDDP) 75 mg/m...
Introduction Endometrial cancer (EC) is the only gynecologic malignancy showing increasing trends in incidence and mortality. While standard treatment has been effective primarily for early-stage EC, precision medicine with tailored therapy revolutionized management of this disease. Genome sequencing analyses have identified four sub-types EC. Treatments primary metastatic disease can now be more accurately to achieve better oncologic results.
Purpose Platinum-based chemotherapy (PBC) for patients with progressing ovarian cancer (OC) is more effective a longer time interval from previous platinum treatment (platinum-free [PFI]). In 1999, it was hypothesized that prolonging PFI single-agent non-PBC (NPBC) may offer strategy to improve overall outcome. MITO-8 aimed verify this hypothesis commonly used in clinical practice although has not been prospectively tested. Methods an open-label, prospective, randomized, superiority trial....
The worldwide approval of the combination maintenance therapy olaparib and bevacizumab in advanced high-grade serous ovarian cancer requires complex molecular diagnostic assays that are sufficiently robust for routine detection driver mutations homologous recombination repair (HRR) genes genomic instability (GI), employing formalin-fixed (FFPE) paraffin-embedded tumor samples without matched normal tissue. We therefore established a DNA-based hybrid capture NGS assay an associated...
5502 Background: The prognosis of advanced or recurrent endometrial cancer (AEC) is dismal. antiangiogenic drug Bevacizumab (B) has reported activity in AEC with response rates ranging from 13 to 22% and 6-month disease control up 40%. This randomized phase II trial was designed compare CP vs CP-B the treatment terms progression free survival (PFS).(EUDRACT Number 003301-16) Methods: Eligible pts had (stage III-IV) (progression > 6 months after completion previous platinum chemotherapy)...